Is Sumitomo a good place to work?
Overall Sumitomo was a ver decent employer with excellent benefits. Excelent culture and work environment, and very competitive compensation. Good management, and very good technical support.
Is Emergent BioSolutions a good company to work for?
Is Emergent BioSolutions a good company to work for? Emergent BioSolutions has an overall rating of 3.3 out of 5, based on over 333 reviews left anonymously by employees. 57% of employees would recommend working at Emergent BioSolutions to a friend and 42% have a positive outlook for the business.
Is Tilray a good place to work?
Is Tilray a good company to work for? Tilray has an overall rating of 2.9 out of 5, based on over 105 reviews left anonymously by employees.
Will HEXO go out of business?
The answer is a resounding “no.” Hexo Corp. is a failing cannabis company, one that is struggling to remain a going concern and avoid both bankruptcy and delisting from the Nasdaq exchange. Massive losses, poor sales, declining market share, and an activist shareholder are hurting the cannabis producer.
Does HEXO have a future?
The 7 analysts offering 12-month price forecasts for Hexo Corp have a median target of 0.19, with a high estimate of 0.39 and a low estimate of 0.12. The median estimate represents a +2.76% increase from the last price of 0.19.
What is it like working at SMBC?
Good job with work life balance, but a struggle with upward mobility. Spent 8 yrs at the company so there is work life balance and jobs security, but the upward mobility has been difficult. Additionally they pay a little less than market, but the bonuses are great.
Who owns Bio port?
BioPort was now a subsidiary of Emergent BioSolutions, led by El-Hibri and his business partners. By the end of 2003, Emergent announced the purchase of a Maryland drug maker for more than $3 million and signed a new contract with the Pentagon, worth from $29.7 million to $245 million, depending on the doses sold.
Why is HEXO doing so poorly?
So what. The main reason Hexo took a bath is because it’s about to launch another in an ever-lengthening series of secondary stock issues. This latest model is taking the form of an at-the-market offering, under which it will selll up to $40 million in fresh common stock.
What are analysts saying about HEXO?
Hexo Corp (NASDAQ:HEXO) The 8 analysts offering 12-month price forecasts for Hexo Corp have a median target of 0.21, with a high estimate of 0.42 and a low estimate of 0.12. The median estimate represents a +6.26% increase from the last price of 0.20.